FcRn Inhibitors: A Potential New Targeted Therapy Option

Guest: Nicholas J. Silvestri, MD FcRn inhibitors provide a targeted approach to generalized myasthenia gravis (gMG) treatment by reducing pathogenic antibodies. These therapies offer fewer side effects compared to traditional treatments like corticosteroids, improving both disease control and quality of life. Dr. Nick Silvestri, a Professor of Neurology at the University of Buffalo Jacobs School of Medicine and Biomedical Sciences, explains this treatment’s potential.